Procedures & recovery · patient guide

Targeted Cancer Therapy in China: Preparing for the First In-Person Discussion

A first in-person discussion about targeted cancer therapy in China works best when you bring a short, written list of questions rather than your whole history. Confirm the specific drug and biomarker context, whether the centre can assess your case, and how any ongoing treatment and monitoring would continue. The hospital, not a coordination service, decides suitability.

Go to the practical guidance ↓
Editorial illustration: Targeted Cancer Therapy in China: Preparing for the First In-Person Discussion
Illustrative image; not a photograph of a named hospital or an identified patient.
In this guide

Why a short question list beats a long story

A first consultation is a limited appointment. The clinician has to understand your cancer type, stage, prior treatments and current status, then decide whether targeted therapy is relevant at all. If you spend the first twenty minutes narrating your whole history, you may leave without answers to the questions that actually change your next step.

Targeted cancer treatment acts on particular molecular features of a tumour, and biomarker findings can help clinicians assess potential treatment options. That is the clinical frame for the conversation. It does not mean every biomarker leads to an available drug, or that a positive result guarantees a response. The purpose of your question list is to find out what the treating team can assess, what they still need, and what they would recommend if targeted therapy is not suitable.

Write your questions before you travel. Keep them to one page. Put the most important question first, because appointments can be shortened. If you are bringing a companion or interpreter, agree in advance who will ask the questions and who will write down the answers.

Confirm the exact drug and biomarker context

The single most useful thing you can clarify is which drug and which biomarker are being discussed. "Targeted therapy" is a broad category, not one treatment. Different drugs act on different molecular features, and the evidence supporting each one depends on the tumour type, the specific alteration and the treatment setting.

Ask directly: which biomarker result is being used to consider this option, and which drug is being proposed? If the answer is vague, ask whether your existing pathology or genomic report contains the relevant information, or whether the team believes further testing is needed. Do not assume that a test you have already had answers the question the clinician is asking.

Bring the actual reports, not a summary. Pathology reports, molecular or genomic testing reports, imaging and a current medication list are the documents a clinician uses to judge whether a targeted option is plausible. If a report is in another language, ask whether a translation is needed and who should provide it. Confirm this with the specific hospital rather than assuming a rule.

It also helps to ask what the goal of treatment would be in your situation. A targeted drug may be discussed with different aims in different settings, and the monitoring plan follows from that aim. Ask the clinician to explain the intended goal in plain terms so you can weigh it against your own priorities.

Ask whether the centre can assess your case

A hospital can only give a meaningful opinion if it has the material and the expertise to review your situation. Before or during the first visit, ask whether the centre can assess your case, and what it still needs in order to do so. This is a practical question, not a challenge to the clinician.

Useful wording: "Based on what you have today, can you assess whether targeted therapy is relevant for me, or do you need additional records or tests first?" Then ask what specifically is missing. If the answer is a pathology block, a genomic report or a recent scan, you can arrange to obtain it. If the answer is that the case needs review by more than one specialty, ask how that review is organised and when you would hear the outcome.

Do not treat a preliminary reply as a final decision. A records-based opinion can clarify options and identify gaps, but it does not establish hospital acceptance, treatment availability or a final plan. Those are decisions for the treating hospital and licensed clinicians after they have assessed you.

How ongoing treatment and monitoring would continue

If you are already receiving treatment, the continuity question matters as much as the drug question. Ask how the centre would handle ongoing treatment and monitoring if you transferred care. Specifically: how would the current regimen be continued or adjusted, what monitoring would be required, and how often would you need to be seen?

These are questions to confirm with the treating team, not facts you can assume from another country's practice. Ask who would be responsible for prescribing and for reviewing results, and how you would be contacted if a result needs action. If you plan to return home between visits, ask how that would work and what the team would need from your local clinician.

Bring a clear list of your current medicines, doses and the dates of recent treatment. Do not change any medicine on your own before the consultation. If you have questions about whether a specific medicine can be brought into China, those are for the customs authorities, not for the hospital or a coordination service.

It is reasonable to ask what would happen if the proposed targeted therapy is not suitable or not available. A good first discussion should leave you knowing the alternatives the team would consider, even if the final recommendation comes later.

Practical preparation for the appointment

Organise your records so the clinician can find the relevant page quickly. A short cover sheet with your diagnosis, stage, prior treatments and current medicines saves time. Put the biomarker and genomic reports on top if targeted therapy is the reason for the visit.

Confirm the appointment details with the hospital or your coordination contact: the department, the clinician's name if known, the address, the interpretation arrangement and what you should bring. These details vary by hospital, so confirm them rather than relying on general assumptions.

If you need interpretation, arrange it in advance and make sure the interpreter understands that you want the answers written down. Ask for the key points in writing if that is possible. A written summary helps you discuss the plan with family and with your clinician at home.

Keep your question list with you during the appointment. Tick off each answer as you receive it. If time runs short, ask which questions can be answered by message afterwards and who will respond.

  • One-page question list, most important question first.
  • Pathology, molecular or genomic reports, imaging and current medication list.
  • Cover sheet with diagnosis, stage, prior treatments and current medicines.
  • Confirmed appointment details and interpretation arrangement.
  • A named person to write down the answers.

Where coordination can help, and what it cannot decide

ChinaSpecialistCare can help with practical, non-clinical coordination: clarifying your main question, identifying missing records, requesting a specialist appointment and arranging interpretation. An initial enquiry is free and does not require buying a proxy consultation. A proxy consultation is optional and is not a prerequisite for an appointment.

What coordination cannot do is decide suitability, prescribe treatment, confirm that a drug is available, or promise hospital acceptance. Those decisions belong to the treating hospital and licensed clinicians. Be cautious of any service that implies otherwise.

The most useful next step is to write your three most important questions and send a brief summary of your diagnosis and current situation. From there, you can confirm what the hospital needs and prepare for the in-person discussion with a clear, limited agenda.

Related treatment reference

Sources & scope of this guide

References and official service information relevant to this guide.

  1. Related treatment reference
  2. NCI: Targeted Therapy for Cancer

This is general planning information and has not been individually reviewed by a doctor. Medical decisions and personal treatment advice come from your treating clinicians.